Company Description
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications.
It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Country | United States |
Founded | 1987 |
IPO Date | Dec 5, 1995 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1,543 |
CEO | John Jacobs |
Contact Details
Address: 700 Quince Orchard Road Gaithersburg, Maryland 20878 United States | |
Phone | 240 268 2000 |
Website | novavax.com |
Stock Details
Ticker Symbol | NVAX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001000694 |
CUSIP Number | 670002401 |
ISIN Number | US6700024010 |
Employer ID | 22-2816046 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
John Charles Jacobs M.B.A. | President, Chief Executive Officer and Director |
John Joseph Trizzino B.S., M.B.A. | President and Chief Operating Officer |
James Patrick Kelly C.F.A. | Executive Vice President, Chief Financial Officer and Treasurer |
Mark Casey | Executive Vice President, Chief Legal Officer and Corporate Secretary |
Richard P. Crowley | Executive Vice President and Chief Operating Officer |
Dr. Robert Walker M.D. | Senior Vice President, Chief Medical Officer and Interim Head of Research & Development |
Troy Morgan Esq., J.D. | Senior Vice President, Deputy General Counsel and Chief Compliance Officer |
Erika S. Trahan | Associate Director of Investor and Public Relations |
Ian J. Watkins | Executive Vice President and Chief Human Resources Officer |
Silvia Taylor M.B.A. | Executive Vice President and Chief Corporate Affairs and Advocacy Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 20, 2024 | 8-K | Current Report |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 12, 2024 | 8-K | Current Report |
Nov 12, 2024 | 8-K | Current Report |
Nov 5, 2024 | 8-K | Current Report |
Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 16, 2024 | 8-K | Current Report |
Oct 3, 2024 | 8-K | Current Report |
Sep 18, 2024 | 144 | Filing |